Filip Dubovsky

7.0k total citations · 1 hit paper
53 papers, 2.6k citations indexed

About

Filip Dubovsky is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Filip Dubovsky has authored 53 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Epidemiology, 13 papers in Infectious Diseases and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Filip Dubovsky's work include Respiratory viral infections research (28 papers), Influenza Virus Research Studies (15 papers) and Pneumonia and Respiratory Infections (15 papers). Filip Dubovsky is often cited by papers focused on Respiratory viral infections research (28 papers), Influenza Virus Research Studies (15 papers) and Pneumonia and Respiratory Infections (15 papers). Filip Dubovsky collaborates with scholars based in United States, United Kingdom and Spain. Filip Dubovsky's co-authors include Therese Takas, Mark T. Esser, Tonya Villafana, M. Pamela Griffin, Anis A. Khan, Joseph B. Domachowske, Judith Falloon, Elissa Malkin, Tingting Yi and Yuan Yuan and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and PLoS ONE.

In The Last Decade

Filip Dubovsky

51 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

2020 456 citations M. Pamela Griffin, Therese Takas et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Filip Dubovsky	1.5k	983	516	362	332	53	2.6k
Hoan Jong Lee	2.9k 1.9×	1.2k 1.2×	451 0.9×	472 1.3×	167 0.5×	190	4.0k
Daniel A. Scott	3.7k 2.5×	1.1k 1.1×	255 0.5×	449 1.2×	411 1.2×	162	5.4k
J. F. P. Schellekens	1.6k 1.0×	1.1k 1.1×	182 0.4×	388 1.1×	406 1.2×	55	3.2k
Claudette M. Thompson	2.8k 1.9×	529 0.5×	305 0.6×	475 1.3×	1.1k 3.4×	74	4.0k
Frank Malinoski	3.1k 2.0×	645 0.7×	347 0.7×	507 1.4×	305 0.9×	50	3.8k
Stephen Lockhart	2.0k 1.3×	932 0.9×	214 0.4×	168 0.5×	672 2.0×	52	3.0k
Rangaraj Selvarangan	1.9k 1.2×	1.8k 1.9×	132 0.3×	234 0.6×	172 0.5×	166	3.5k
Malcolm Guiver	2.6k 1.7×	1.0k 1.0×	229 0.4×	367 1.0×	336 1.0×	88	3.9k
Alireza Eshaghi	1.5k 1.0×	793 0.8×	181 0.4×	111 0.3×	121 0.4×	62	2.1k
Deborah F. Talkington	2.3k 1.5×	731 0.7×	281 0.5×	726 2.0×	425 1.3×	62	4.0k

Countries citing papers authored by Filip Dubovsky

Since Specialization

Citations

This map shows the geographic impact of Filip Dubovsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Dubovsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Dubovsky more than expected).

Fields of papers citing papers by Filip Dubovsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Dubovsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Dubovsky. The network helps show where Filip Dubovsky may publish in the future.

Co-authorship network of co-authors of Filip Dubovsky

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Dubovsky. A scholar is included among the top collaborators of Filip Dubovsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Dubovsky. Filip Dubovsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Nita, Rhonda Flores, Mimi Guebre‐Xabier, et al.. (2025). Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin–Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nature Communications. 16(1). 6625–6625.

Patel, Nita, Jessica F. Trost, Mimi Guebre‐Xabier, et al.. (2023). XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Scientific Reports. 13(1). 19176–19176. 36 indexed citations

Formica, Neil, Raburn M. Mallory, Gary Albert, et al.. (2021). Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Medicine. 18(10). e1003769–e1003769. 64 indexed citations

Ali, Omar, Xiang‐Qing Yu, Gabriel J. Robbie, et al.. (2018). Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clinical Microbiology and Infection. 25(5). 629.e1–629.e6. 92 indexed citations

Mallory, Raburn M., Omar Ali, Therese Takas, et al.. (2017). A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. Biologicals. 50. 81–86. 18 indexed citations

Griffin, M. Pamela, Anis A. Khan, Mark T. Esser, et al.. (2016). Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 61(3). 113 indexed citations

Falloon, Judith, Fei Ji, Craig Curtis, et al.. (2016). A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine. 34(25). 2847–2854. 50 indexed citations

Malkin, Elissa, Ram Yogev, Nazha Abughali, et al.. (2013). Safety and immunogenicity of a live attenuated intranasal vaccine against respiratory syncytial virus in healthy RSV seronegative children 5 to 24 months of age.. PLoS ONE. 8(10). 6 indexed citations

Sheldon, Eric, Robert Jeanfreau, Joseph Sliman, et al.. (2012). Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study*. Influenza and Other Respiratory Viruses. 7(6). 1142–1150. 13 indexed citations

10.

Block, Stan L., Judith Falloon, Leonard R. Krilov, et al.. (2012). Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children. The Pediatric Infectious Disease Journal. 31(7). 745–751. 58 indexed citations

11.

Bruder, Joseph T., Noelle B. Patterson, Ping Chen, et al.. (2010). Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine. 28(18). 3201–3210. 32 indexed citations

12.

Gomez, Margarita, et al.. (2009). PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN. The Pediatric Infectious Disease Journal. 28(7). 655–658. 56 indexed citations

13.

Sacarlal, Jahit, John J. Aponte, Pedro Aíde, et al.. (2007). Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine. 26(2). 174–184. 22 indexed citations

14.

Saul, Allan, Meike Hensmann, Jetsumon Sattabongkot, et al.. (2007). Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite Immunology. 29(10). 525–533. 23 indexed citations

15.

Malkin, Elissa, et al.. (2006). Progress towards the development of malaria vaccines. Trends in Parasitology. 22(7). 292–295. 35 indexed citations

16.

Enosse, Sónia, Carlota Dobaño, John J. Aponte, et al.. (2006). RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection. PubMed. 1(1). e5–e5. 53 indexed citations

17.

Giersing, Birgitte, et al.. (2006). Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine. 24(20). 4264–4270. 20 indexed citations

18.

Macete, Eusébio, John J. Aponte, Caterina Guinovart, et al.. (2006). Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique. Tropical Medicine & International Health. 12(1). 37–46. 30 indexed citations

19.

Langermans, Jan A. M., Annette M. Schmidt, Richard A. W. Vervenne, et al.. (2005). Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine. 23(41). 4935–4943. 22 indexed citations

20.

Okeke, Iruka N., Adebayo Lamikanra, John R. Czeczulin, et al.. (2000). Heterogeneous Virulence of EnteroaggregativeEscherichia coliStrains Isolated from Children in Southwest Nigeria. The Journal of Infectious Diseases. 181(1). 252–260. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact